| Date Filed | Type | Description |
| 04/13/2021 |
8-K
| Quarterly results |
| 04/12/2021 |
8-K
| Quarterly results |
| 03/08/2019 |
8-K
| Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...|
Docs:
|
"EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is entered into as of March 7, 2019, by and between Gary H. Rabin , and Immune Pharmaceuticals Inc . Company desires to engage Rabin as President and Interim Chief Executive Officerto provide certain services to Company as more particularly set forth in Exhibit A attached hereto and made a part hereof . The parties desire to set forth, in writing, the terms and conditions concerning the engagement. Accordingly, in consideration of the mutual covenants in this Agreement, and for other good and valuable consideration, it is agreed as follows: 1. Engagement and Commencement Date. Commencing on March 7, 2019 , Company hereby engages Rabin as President and Interim Chief Executive Officer, on the terms and conditions set forth in this Agreement. By ...",
"Investor Contact" |
|
| 02/14/2019 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 12/19/2018 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 12/06/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/28/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/26/2018 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 10/22/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 10/10/2018 |
8-K
| Quarterly results |
| 09/18/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 09/10/2018 |
8-K
| Resignation/termination of a director |
| 07/26/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 06/08/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 05/14/2018 |
8-K
| Quarterly results |
| 05/07/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/28/2018 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/12/2018 |
8-K
| Investor presentation |
| 02/08/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/26/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/09/2018 |
8-K
| Investor presentation |
| 12/14/2017 |
8-K/A
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 12/06/2017 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 12/04/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/27/2017 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 11/17/2017 |
8-K
| Other Events, Financial Statements and Exhibits |
| 10/25/2017 |
8-K
| Quarterly results |
| 10/23/2017 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"IMMUNE PHARMACEUTICALS INC. ANNOUNCES CLOSING OF $18,000,000 PUBLIC OFFERING OF CONVERTIBLE PREFERRED STOCK AND WARRANTS ENGLEWOOD CLIFFS, N.J., – Immune Pharmaceuticals Inc. a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune. The offering was comprised of units, priced at a public offering price of $1,000 per unit. Each unit consists of one share of Series E Convertible Preferred Stock and 982 warrants , each of which entitles the holder to purchase one share of Immune’ s common stock. The Warrants are initial...",
"About Immune Pharmaceuticals Inc." |
|
| 10/03/2017 |
8-K
| Investor presentation |
| 09/08/2017 |
8-K
| Quarterly results |
| 08/29/2017 |
8-K
| Quarterly results |
| 08/24/2017 |
8-K
| Quarterly results |
| 08/18/2017 |
8-K
| Quarterly results |
| 07/18/2017 |
8-K
| Form 8-K - Current report: |
|